Patents by Inventor Matthews O. Bradley

Matthews O. Bradley has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Carbazole compounds and methods of use thereof
    Patent number: 11655244
    Abstract: Described herein are compounds, pharmaceutical compositions and methods that are useful as S-nitrosoglutathione reductase (GSNOR) inhibitors.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: May 23, 2023
    Assignee: GSNO Therapeutics, Inc.
    Inventors: Richard J. Pariza, Matthews O. Bradley
  • Fatty acid-pharmaceutical agent conjugates
    Patent number: 8314077
    Abstract: The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: November 20, 2012
    Assignee: Luitpold Pharmaceuticals, Inc.
    Inventors: Nigel L. Webb, Matthews O. Bradley, Charles S. Swindell, Victor E. Shashoua
  • FATTY ACID-ANTICANCER CONJUGATES AND USES THEREOF
    Publication number: 20080125380
    Abstract: The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided.
    Type: Application
    Filed: June 21, 2007
    Publication date: May 29, 2008
    Applicant: Luitpold Pharmaceuticals, Inc.
    Inventors: Nigel L. Webb, Matthews O. Bradley, Forrest Anthony, Mark Fisher
  • Fatty acid-anticancer conjugates and uses thereof
    Patent number: 7235583
    Abstract: The invention provides conjugates of fatty acids and anticancer agents useful in treating cancer, and compositions and formulations thereof. Methods for using the conjugates also are provided.
    Type: Grant
    Filed: March 9, 1999
    Date of Patent: June 26, 2007
    Assignee: Luitpold Pharmaceuticals, Inc.,
    Inventors: Nigel L. Webb, Matthews O. Bradley, Forrest Anthony, Mark Fisher
  • DHA-pharmaceutical agent conjugates of taxanes
    Patent number: 7199151
    Abstract: The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.
    Type: Grant
    Filed: July 14, 2003
    Date of Patent: April 3, 2007
    Assignee: Luitpold Pharmaceuticals, Inc.
    Inventors: Victor E. Shashoua, Charles E. Swindell, Nigel L. Webb, Matthews O. Bradley
  • DHA-pharmaceutical agent conjugates of taxanes
    Publication number: 20040180949
    Abstract: The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.
    Type: Application
    Filed: July 14, 2003
    Publication date: September 16, 2004
    Applicant: Protarga, Inc.
    Inventors: Victor E. Shashoua, Charles E. Swindell, Nigel L. Webb, Matthews O. Bradley
  • Fatty acid-pharmaceutical agent conjugates
    Publication number: 20040106589
    Abstract: The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.
    Type: Application
    Filed: June 5, 2003
    Publication date: June 3, 2004
    Applicant: Protarga Pharmaceuticals, Inc.
    Inventors: Nigel L. Webb, Matthews O. Bradley, Charles S. Swindell, Victor E. Shashoua
  • Dha-pharmaceutical agent conjugates to improve tissue selectivity
    Patent number: 6602902
    Abstract: The invention provides conjugates of cis-docosahexaenoic acid and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.
    Type: Grant
    Filed: May 1, 2001
    Date of Patent: August 5, 2003
    Assignee: Protarga, Inc.
    Inventors: Victor E. Shashoua, Charles E. Swindell, Nigel L. Webb, Matthews O. Bradley
  • Method of treating a liver disorder with fatty acid-antiviral agent conjugates
    Patent number: 6576636
    Abstract: The invention provides conjugates of fatty acids and antiviral agents useful in treating liver disorders.
    Type: Grant
    Filed: December 5, 2000
    Date of Patent: June 10, 2003
    Assignee: Protarga, Inc.
    Inventors: Nigel L. Webb, Matthews O. Bradley, Charles S. Swindell, Victor E. Shashoua
  • Nucleoside analog compositions and uses thereof
    Publication number: 20020025943
    Abstract: The invention provides compositions that include conjugates of a carrier molecule, preferably cis-docosahexaenoic acid, and 2′,3′-dideoxycytidine. The conjugates are useful in treating viral infections, especially retroviral infections, and particularly reservoirs of viral infection in peripheral T cells and central nervous system manifestations thereof.
    Type: Application
    Filed: September 6, 2001
    Publication date: February 28, 2002
    Inventors: Matthews O. Bradley, Charles S. Swindell, Nigel L. Webb, Victor Shashoua
  • Fatty acid-pharmaceutical agent conjugates
    Publication number: 20010002404
    Abstract: The invention provides conjugates of fatty acids and pharmaceutical agents useful in treating noncentral nervous system conditions. Methods for selectively targeting pharmaceutical agents to desired tissues are provided.
    Type: Application
    Filed: December 5, 2000
    Publication date: May 31, 2001
    Inventors: Nigel L. Webb, Matthews O. Bradley, Charles S. Swindell, Victor E. Shashoua
  • Clozapine compositions and uses thereof
    Patent number: 6197764
    Abstract: The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and clozapine. The conjugates are useful in treating psychological disorders such as schizophrenia.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: March 6, 2001
    Assignee: Protarga, Inc.
    Inventors: Matthews O. Bradley, Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb
  • Taxanes
    Patent number: 6080877
    Abstract: The invention provides taxanes that are conjugates of cis-docosahexaenoic acid and taxotere. The conjugates are useful in treating cancer.
    Type: Grant
    Filed: June 3, 1997
    Date of Patent: June 27, 2000
    Assignee: Neuromedica, Inc.
    Inventors: Charles S. Swindell, Victor E. Shashoua, Matthews O. Bradley, Nigel L. Webb
  • Cholinergic compositions and uses thereof
    Patent number: 5977174
    Abstract: The invention provides compositions that include conjugates of a cholinergic agent and a fatty acid, preferably cis-docosahexaenoic acid. The conjugates are useful in treating disorders resulting from cerebral ischemia including stroke.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: November 2, 1999
    Assignee: Neuromedica, Inc.
    Inventors: Matthews O. Bradley, Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb
  • Fatty acid-antipsychotic compositions and uses thereof
    Patent number: 5955459
    Abstract: The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and antipsychotic agents. The conjugates are usefull in treating psychotic conditions such as schizophrenia.
    Type: Grant
    Filed: November 26, 1997
    Date of Patent: September 21, 1999
    Assignee: Neuromedica, Inc.
    Inventors: Matthews O. Bradley, Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb
  • Taxane compounds and compositions
    Patent number: 5919815
    Abstract: The invention provides taxanes that are conjugates of cis-docosahexaenoic acid and paclitaxel. The conjugates are useful in treating cancer.
    Type: Grant
    Filed: May 22, 1996
    Date of Patent: July 6, 1999
    Assignee: Neuromedica, Inc.
    Inventors: Matthews O. Bradley, Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb
  • DHA-pharmaceutical agent conjugates of taxanes
    Patent number: 5795909
    Abstract: The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.
    Type: Grant
    Filed: May 22, 1996
    Date of Patent: August 18, 1998
    Assignee: Neuromedica, Inc.
    Inventors: Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb, Matthews O. Bradley
  • Antisense oligonucleotides directed against human VCAM-1 RNA
    Patent number: 5596090
    Abstract: Antisense oligonucleotides complementary to human mRNAs or pre-mRNAs coding or VCAM-I are used in a therapeutic treatment of sepsis (sepsis, the sepsis syndrome, septic shock and all other manifestations of the sepsis disease, including but not inclusive of, adult respiratory distress syndrome, multi-organ failure, or cardiovascular dysfunction).
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: January 21, 1997
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Glenn D. Hoke, Matthews O. Bradley, Taffy J. Williams, Che-Hung Lee
  • Antisense oligonucleotides directed against human ELAM-I RNA
    Patent number: 5585479
    Abstract: The present invention provides a method for the treatment of septic shock d inflammatory complications of shock. A process for selectively inhibiting the expression of the human ELAM-I mRNA transcript using at least one oligonucleotide which is substantially complementary to at least a portion of the ELAM-I gene is disclosed, as are composition comprising the oligonucleotide.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: December 17, 1996
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Glenn D. Hoke, Matthews O. Bradley, Taffy J. Williams, Che-Hung Lee
  • Antisense oligonucleotides directed against human ICAM-I RNA
    Patent number: 5580969
    Abstract: The present invention provides a method for the treatment of septic shock and inflammatory complications of shock. A process for selectively inhibiting the expression of the human ICAM-I mRNA transcript using at least one oligonucleotide which is complementary to at least a portion of the human ICAM-I mRNA is disclosed, as are oligonucleotides which are complementary to portions of the ICAM-I mRNA and compositions comprising the oligonucleotides.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: December 3, 1996
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventors: Glenn D. Hoke, Matthews O. Bradley, Taffy J. Williams, Che-Hung Lee